Brainsway Ltd.BWAY
Price (close)
$13.31
Market cap
$535.6M
P/E
—
Revenue (FY)
$41.0M
Net income
$2.9M
Dividend yield
—
1-year total return
78.5%
Net margin
7.1%
Revenue growth
29.0%
Debt / equity
—
What Brainsway Ltd. does.
neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial
Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. We are dedicated to leading through
superior science and building on what we believe to be an unparalleled body of clinical evidence. We are the first and only TMS company
Revenue and profit, by fiscal year.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | $23.1M | $22.1M | $29.7M | $27.2M | $31.8M | $41.0M |
| Net income | -$10.3M | -$5.4M | -$6.5M | -$13.3M | -$4.2M | $2.9M |
| Free cash flow | -$10.6M | -$3.9M | -$1.4M | — | — | — |
More on BWAY.
- Brainsway Ltd. summary
- Brainsway Ltd. financial statements
- Brainsway Ltd. key metrics
- Brainsway Ltd. health scores and style box
- Brainsway Ltd. earnings
- Brainsway Ltd. dividends
- Brainsway Ltd. valuation
- Brainsway Ltd. ownership and insiders
- Brainsway Ltd. peers
Figures from Brainsway Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.